Molecular Analysis for Therapy Choice (MATCH)

Contact:

212-342-5162

NCT Number:

NCT02465060

Protocol:

AAAP9159

Study Status:

Closed to Accrual, Study Active

Population:

Adult

Phase:

II

To evaluate the proportion of patients with objective response (OR) to targeted study agent(s) in patients with advanced refractory cancers/lymphomas.

Are you Eligible? (Inclusion Criteria)

  • Patients must be >= 18 years of age.
  • Patients with advanced refractory cancers/lymphomas

Specialty Area(s)

Bladder Cancer , Brain and Spinal Tumors, Breast Cancer, Cervical Cancer, Ovarian Cancer, Head and Neck/Oral Cancers, Lung cancer, Hodgkin's Disease, Non-Hodgkin's Lymphoma, Skin cancers, Melanoma, Pancreatic Cancer, Prostate Cancer, Sarcomas (Bone and Soft Tissue), Testicular Cancer, Thyroid Cancer, Precision Oncology

Principal Investigator

Brian Henick, MD

Profile Headshot
  • Associate Director, Experimental Therapeutics
  • Director of Translational Research, Upper Aerodigestive Cancers in Medical Oncology

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
Open location in Google Maps